drugset / Trial / NCT00859716
ACE393-103 Vaccination Challenge Study
Phase 2
Unknown
72 enrolled
TD Vaccines A/S
Fulcrum Pharma (Europe) Ltd · collabJohns Hopkins University · collabSGS U.S. Testing Company Inc. · collabSNBL Clinical Pharmacology Center, Inc. · collabUniversity of Vermont · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to determine whether ACE393 vaccination can protect against Campylobacteriosis in a challenge model.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-03
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACE393 | Vaccine | 250 ug | Intramuscular |